Carney Complex Cardiac Risk Assessment

Assess cardiac myxoma risk in Carney complex (PRKAR1A mutation) using annual echocardiography findings, spotty pigmentation extent, and endocrine tumor screening results.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess cardiac myxoma risk in Carney complex (PRKAR1A mutation) using annual echocardiography findings, spotty pigmentation extent, and endocrine tumor screening results

Each component has a specific meaning:

  • Annual echocardiography findings — The annual echocardiography findings recorded for the scenario being assessed.
  • Spotty pigmentation extent — The spotty pigmentation extent recorded for the scenario being assessed.
  • Endocrine tumor screening results — The endocrine tumor screening results recorded for the scenario being assessed.

Note: Interpret the carney complex cardiac risk result against the thresholds and context described above.

How to Use

Enter the annual echocardiography findings, spotty pigmentation extent, endocrine tumor screening results for the scenario you are assessing. Assess cardiac myxoma risk in Carney complex (PRKAR1A mutation) using annual echocardiography findings, spotty pigmentation extent, and endocrine tumor screening results. Use the carney complex cardiac risk result to inform your calculation.

Frequently Asked Questions